Evidence map›Paper›PMID 41463300›Full record

ReviewBiomolecules2025

Emerging Role of Calycosin in Inflammatory Diseases: Molecular Mechanisms and Potential Therapeutic Applications.

Tongzhan Liu, Yifei Ye, Yu Hu, Meixiu Jiang

Abstract readReview
In one paragraph

Review in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tongzhan LiuThe Queen Mary School, Jiangxi Medical College, Nanchang University, 999 Xuefu Road, Nanchang 330031, China.ORCID 0009-0009-8284-9043
Yifei YeSchool of Pharmacy, Jiangxi Medical College, Nanchang University, 999 Xuefu Road, Nanchang 330031, China.
Yu HuJiangxi Province Key Laboratory of Bioengineering Drugs, The National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, 999 Xuefu Road, Nanchang 330031, China.
Meixiu JiangJiangxi Province Key Laboratory of Bioengineering Drugs, The National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, 999 Xuefu Road, Nanchang 330031, China.

Funding

Jiangxi province Science and Technology Program of the Health Commission 202311127National Natural Science Foundation of China 82160094National Natural Science Foundation of China 82200509Natural Science Foundation of Jiangxi Province 20252BAC240143The Jiangxi Province Key Laboratory of bioengineering drugs 2024SSY07061
6 · The paper itself

Abstract

Inflammatory diseases are a type of disease caused by multiple factors, which are characterized by local or systemic tissue inflammatory reactions, commonly including atherosclerosis, osteoarthritis, non-alcoholic fatty liver, chronic kidney diseases, acute pancreatitis, and tumors. The prevalence of the above diseases is globally high and a growing threat to human health, as well as a huge healthcare burden. In recent years, Chinese herbal medicines have become an important reservoir for the discovery of new drugs and applications due to their unique molecular structures and potential biotherapeutic effects. Numerous studies have confirmed the beneficial effects of natural products in the prevention and treatment of different diseases. Scientific studies on the therapeutic potential of natural products have become a hot topic nowadays, especially regarding the active ingredients of herbs. Calycosin is a kind of isoflavonoid extracted from the root of

Indexed as

Anti-Inflammatory AgentsInflammationIsoflavonesAnimalsDrugs, Chinese HerbalHumansNeoplasms7,3'-dihydroxy-4'-methoxyisoflavoneAnti-Inflammatory AgentsDrugs, Chinese HerbalIsoflavonesanti-inflammationanti-oxidationcalycosinChinese herbal medicineinflammatory diseasestherapeutic potential

Identifiers

PMID41463300
PMCPMC12730483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.